Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28277238 | 0.86 | ALDH1A1 (0.53) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| Sulfuric Acid SCHEMBL4454713 | 0.86 | ALDH1A1 (0.53) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL42904 | 0.85 | — | — | |
| SCHEMBL5565016 | 0.85 | DPP4 (0.58) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL29380238 | 0.85 | — | — | |
| SCHEMBL24932018 | 0.85 | DPP4 (0.58) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL5559781 | 0.85 | DPP4 (0.58) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL4916236 | 0.85 | DPP4 (0.58) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL42393 | 0.85 | — | — | |
| SCHEMBL830 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271955-A1 | NOVEL TARGETED SHRNA NANOPARTICLES FOR CANCER THERAPY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-28 | — | — | US | disclosed |
| US-7455840-B2 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1689852-A2 | COMPOSITIONS AND METHODS TO REDUCE MUTAGENESIS | The Scripps Research Institute (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060111302-A1 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE & ACHAOGEN, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005056754-A2 | COMPOSITIONS AND METHODS TO REDUCE MUTAGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20030119038-A1 | NARC1, novel subtilase-like homologs | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | OGG1, DNMT3A, APOBEC3G | LMNA 2219/4885KDM4E 873/4885ADRA2A 1480/4885 |
| US-20060111302-A1 | Compositions and methods to reduce mutagenesis | OGG1, DNMT3A, APOBEC3G | LMNA 2219/4885KDM4E 873/4885ADRA2A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.